Business
Evogene and Shanghai Lishan Biopharmaceuticals Seal USD Global Microbiome Cancer Therapeutic Licensing Deal
Evogene Ltd. and Shanghai Lishan Biopharmaceuticals Co. have [announced an exclusive worldwide licensing agreement](https://www.prnewswire.com/news-releases/evogene-and-shanghai-lishan-biopharmaceuticals-co-announce-exclusive-licensing-agreement-for-bmc128-a-microbiome-based-therapeutic-for-renal-and-lung-cancer-302678749.html) for BMC128, a first-in-class microbiome-based therapeutic targeting re
PranaX Secures $17 Million Series A Funding to Advance Exosome Regenerative Medicine Technology
Houston-based regenerative biologics startup PranaX Corporation has secured $17 million in an oversubscribed Series A funding round, signaling growing investor interest in cutting-edge exosome wellness technologies. The startup funding round was led by a consortium of family offices, trusts, and individual investors with deep expertise across biotechnology, regenerative medicine, and healthcare in
Moderna and Recordati Seal $160M mRNA Rare Disease Therapy Development Deal
Moderna and Recordati have announced a strategic collaboration to develop and commercialize mRNA-3927, an investigational therapy for propionic acidemia (PA), marking a significant business partnership news event in the rare disease therapeutics space. Under the agreement, Moderna will lead clinical development while Recordati will manage global commercialization, combining the biotech leader's mR
Lilly Invests $1.9B in Repertoire's DECODE Platform for Precision Autoimmune Therapy
Lilly Taps Repertoire's DECODE Platform for Tolerizing Autoimmune Therapies in USD 1.9B Deal Eli Lil...
PAQ Therapeutics Raises $77 Million in Series B to Advance KRAS Degrader Cancer Therapies
PAQ Therapeutics Secures USD 77 Million in Series B Financing to Advance KRAS Degrader Pipeline PAQ Therapeutics, a Burlington, Massachusetts-based biotech com...
Think Bioscience Raises $55 Million Series A to Advance Rare Disease Drug Discovery Platform
Think Bioscience Secures USD 55 Million to Advance Rare Disease Pipeline Boulder, Colorado-based Thi...
Exciva Raises EUR 51 Million Series B to Advance Groundbreaking Alzheimer's Therapy
Exciva Secures EUR 51 Million to Advance Alzheimer's Therapy Stockholm-based biotech company Exciva ...
Kinaset Therapeutics Raises $103 Million Series B to Advance Inhaled Asthma Drug Therapy
Kinaset Therapeutics Secures USD 103 Million to Advance Inhaled Asthma Therapy Boston-based Kinaset ...
Mediar Therapeutics Raises $76 Million in Series B to Advance Anti-Fibrotic Drug Pipeline
Mediar Therapeutics Secures USD 76 Million to Advance Anti-Fibrotic Pipeline Boston-based Mediar The...
The AllSci Brief
Systematic R&D and deal news. Daily.